Most of these interactions are relatedto TKIs, especially those used to treat advanced lung cancer with activatingmutations (EGFR—afatinib and osimertinib; ALK—crizotinib; KRAS—dabrafenib andvemurafenib),41 breast cancer (lapatinib and ribociclib), and other typesof solid malignant tumors involving multikinase inhibitors (lenvatinib, sorafenib,sunitinib, and vandetanib).42 The interaction between azithromycin and antineoplasticagents appears to be related to pharmacodynamic mechanisms, characterized by anincreased risk of changes in cardiac parameters.43 Here, KRAS is linked to breast cancer.